Compare Heron Therapeutics Inc (HRTX) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MakeMyTrip Ltd — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while MakeMyTrip Ltd trades at $60.56 (market cap $5.78B). The key difference: MakeMyTrip Ltd is far larger — about 94× Heron Therapeutics Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MMYT | |
|---|---|---|
Market Cap | $61.47M | $5.78B |
Sector | Health | Technology |
52-Week High | $1.49 | $103.21 |
52-Week Low | $0.32 | $36.30 |
Enterprise Value | $168.21M | $6.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.
Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
